Qiagen N.V. (QGEN)
- Previous Close
39.47 - Open
39.64 - Bid --
- Ask --
- Day's Range
39.64 - 40.14 - 52 Week Range
34.74 - 47.70 - Volume
886,370 - Avg. Volume
1,020,446 - Market Cap (intraday)
8.854B - Beta (5Y Monthly) 0.42
- PE Ratio (TTM)
26.14 - EPS (TTM)
1.53 - Earnings Date Apr 29, 2024
- Forward Dividend & Yield 1.28 (2.94%)
- Ex-Dividend Date Jan 30, 2024
- 1y Target Est
50.97
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
www.qiagen.com5,191
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: QGEN
Performance Overview: QGEN
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: QGEN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: QGEN
Valuation Measures
Market Cap
8.74B
Enterprise Value
9.21B
Trailing P/E
25.87
Forward P/E
18.48
PEG Ratio (5yr expected)
1.22
Price/Sales (ttm)
4.49
Price/Book (mrq)
2.29
Enterprise Value/Revenue
4.69
Enterprise Value/EBITDA
13.38
Financial Highlights
Profitability and Income Statement
Profit Margin
17.37%
Return on Assets (ttm)
4.49%
Return on Equity (ttm)
9.38%
Revenue (ttm)
1.97B
Net Income Avi to Common (ttm)
341.3M
Diluted EPS (ttm)
1.53
Balance Sheet and Cash Flow
Total Cash (mrq)
1.06B
Total Debt/Equity (mrq)
44.91%
Levered Free Cash Flow (ttm)
156.91M
Research Analysis: QGEN
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Research Reports: QGEN
Analyst Report: Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (over 45% of 2022 sales), followed by EMEA (nearly 35%), and Asia-Pacific (nearly 20%).
RatingBullishPrice TargetAnalyst Report: Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (over 45% of 2022 sales), followed by EMEA (nearly 35%), and Asia-Pacific (nearly 20%).
RatingBullishPrice TargetAnalyst Report: Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (over 45% of 2022 sales), followed by EMEA (nearly 35%), and Asia-Pacific (nearly 20%).
RatingBullishPrice TargetAnalyst Report: Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (45% of 2021 sales), followed by EMEA (36%), and Asia-Pacific (19%).
RatingBullishPrice Target